# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-04-02T11:28:58.275303

---

**Idea Fidelity**  
The paper closely follows the manifest idea: it leverages Colombia’s staggered SECOP II rollout, combines SECOP Integrado with SECOP II Procesos data, and frames the research question around competition versus single-bidder contracts. The identification strategy—staggered DiD using department-level SECOP II intensity as treatment and direct contracting as a placebo—is implemented largely as described. One deviation is that the DiD analysis aggregates to the department-quarter level rather than the entity-level, which was suggested in the manifest. This aggregation is defensible given entity identifier incompatibilities across platforms, but it attenuates the granularity implied by the original idea.

**Summary**  
The paper argues that Colombia’s transition from the informational SECOP I to the transactional SECOP II platform increased competitive bidding in public procurement. Using a department-quarter panel and a continuous treatment variable capturing SECOP II penetration, it shows large increases in the share of competitive modalities and decreased single-bidder rates among early adopters, while showing no effect on direct contracting. The authors interpret the results as evidence that reducing participation costs, not just better information disclosure, is the key constraint on competition.

**Essential Points**

1. **Causal Interpretation of Continuous Treatment Coefficient**  
   The preferred specification reports a 25.6 percentage point increase in the competitive share per unit increase in SECOP II share. Yet the treatment variable is mechanically tied to the outcome—when more contracts are processed on SECOP II, institutional rules already mandate that those contracts be competitive, so the coefficient largely captures the accounting relationship rather than a behavioral response. It is unclear how much of this estimate reflects actual increases in competitive bidding versus substitution of existing competitive contracts onto the transactional platform. The authors need to clarify why there is still meaningful variation in competition conditional on SECOP II share, or else rely on the binary post indicator and interpret results more cautiously. Without this, the identified effect is tautological and cannot answer the stated research question.

2. **Parallel Trends and Rollout Endogeneity**  
   The identification relies on staggered adoption driven by rollout sequencing. However, the timing of SECOP II adoption could correlate with unobserved department-level shocks to procurement capacity or with digitization readiness that also affect competition, especially since the rollout prioritized national and more capable entities. The paper should present event-study graphs (not just mention they exist in an appendix) to demonstrate pre-trends across early and late adopters, and test for differential timing using observable department characteristics. Otherwise the parallel trends assumption remains untested and threatens the credibility of the DiD.

3. **Mechanism Evidence Beyond Process-Level Comparison**  
   The process-level comparison (early vs. late adopters within SECOP II) is interpreted as evidence that transaction costs constrain competition. But this comparison is cross-sectional and may suffer from selection: early adopters could differ systematically in unobserved ways (e.g., more capacity, better procurement staff) that affect bidder participation even net of time and modality controls. Instrumental variation or an event study around each entity’s first SECOP II process would provide stronger evidence that competition increases as entities transition, rather than reflecting persistent heterogeneity. Without it, the mechanism remains suggestive rather than causal.

**Suggestions**

1. **Reframe the Treatment Variable**  
   Given the mechanical link between platform usage and the definition of a competitive contract, focus interpretation on the binary adoption indicator rather than the continuous share, or clarify what variation remains once contracts are on SECOP II. For instance, consider an alternative outcome such as the number of competitive contracts among entities that already adopted but differ in intensity, or the change in supplier counts conditional on processing modality, to isolate behavioral responses from mechanical shifts.

2. **Strengthen Event-Study Evidence**  
   Include the event-study figures (currently only referred to in the appendix) in the main text to show pre-trend patterns for key outcomes (competitive share, direct contracting). If staggered adoption leads to non-parallel pre-trends, consider employing Callaway and Sant’Anna (2021) or Sun and Abraham (2021) estimators and report cohort-specific ATT to ensure robustness to heterogeneous treatment effects.

3. **Control for Time-Varying Department Characteristics**  
   While department fixed effects absorb time-invariant heterogeneity, departments may experience differential secular trends (e.g., economic growth, investment in administrative capacity) that correlate with SECOP II adoption. Including department-specific linear trends, or controlling directly for observable time-varying covariates (e.g., GDP per capita, budget size, number of entities adopting), would mitigate concerns about omitted dynamics.

4. **Address the Influence of Bogot á More Transparently**  
   The robustness table shows results excluding Bogotá, but the binary treatment remains positive even without it. Report the baseline treatment effect alongside coefficient plots with and without large departments to assess leverage more thoroughly. If Bogotá dominates, reweighting or running separate analyses for small and large departments may provide more nuanced inference.

5. **Clarify Mechanism via Procurement Value or Supplier Diversity**  
   To bolster the claim that participation costs drive the effect, analyze whether supplier diversity (unique suppliers, share of small firms) increases following adoption, or whether average contract values decline, using the Integrado data. These additional outcomes would triangulate the mechanism beyond bidder counts and show whether more firms are participating, not merely moving contracts online.

6. **Discuss the Geographical Aggregation Trade-off**  
   Since entity identifiers do not align across SECOP I and II, highlight more explicitly the consequences of aggregating to the department level for the DiD. For example, show how much of the treated sample consists of national agencies versus municipalities, and whether department-level adoption timing accurately captures the degree of exposure for underlying entities.

7. **Elaborate on Placebo Validity**  
   The direct contracting placebo is a useful diagnostics, but clarify why direct contracting should remain unaffected if competition rises (e.g., is it exempt from SECOP II?). If direct contracting also migrates to SECOP II for administrative reasons, the placebo loses power. Consider additional falsification tests using modalities unlikely to change (e.g., mandated special regime contracts).

8. **Expand Discussion of External Validity and Limitations**  
   The conclusion claims general lessons for digital government. Temper this by discussing how Colombia’s institutional context (e.g., strong central procurement agency, relatively high digital infrastructure) may affect generalizability, and note that the effects capture voluntary adoption before the 2022 mandate, potentially differing from rollout contexts elsewhere.

By addressing these points, the paper can more convincingly argue that transactional e-procurement increases competition and clarify the credibility of its identification strategy.
